12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Convivia: Phase IIa data

In a double-blind, dose-escalation, U.S. Phase IIa trial in 32 patients of Japanese descent with ALDH2 deficiency, oral Convivia significantly reduced heart palpitations following alcohol consumption. Convivia also...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >